Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Vaccine Reaction
Interventions: FMP013, ALFQ; Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Age-related Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Povidone Iodine, Hypochlorous Acid; Other
Lead sponsor: California Retina Consultants; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Overactive Bladder
Interventions: Macrobid® Capsules 100 mg, Standard Medical Care (SMC); Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Congenital Ichthyosis
Interventions: PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%, Vehicle for PAT-001 0.2%; Drug
Lead sponsor: Patagonia Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: San Diego, California • New Haven, Connecticut • Chicago, Illinois + 2 more

Conditions: Pharmacologic Action
Interventions: Primaquine; Drug
Lead sponsor: Walter Reed Army Institute of Research (WRAIR); Federal
Eligibility: 18 Years to 60 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Small Cell Lung Cancer Extensive Stage
Interventions: Gocatamig, I-DXd, Atezolizumab, Carboplatin, Etoposide, Rescue Medications; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 13
States / cities: Santa Rosa, California • Aurora, Colorado • Orlando, Florida + 10 more

Conditions: Airway Obstruction
Interventions: McMurray Enhanced Airway, Nasal Cannula; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: CYP2C19 Genetic Variants
Interventions: Limonene; Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg, Odalasvir 75 mg, AL-335 800 mg, Lansoprazole 30 mg, Omeprazole 20 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Advanced Solid Tumor
Interventions: GS-5319, Carboplatin, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Boston, Massachusetts • New Brunswick, New Jersey • San Antonio, Texas + 1 more

Conditions: Diet, Food and Nutrition
Interventions: UPF Test Diet A: Starchy, refined grains, UPF Test Diet B: Meat, fish, and bread products, UPF Diet C: Dairy products, including cheese and cream; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 20 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Phenylketonuria
Interventions: PTC923, Placebo; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Not listed
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Stanford, California • Aurora, Colorado • Gainesville, Florida + 9 more

Conditions: Schizophrenia
Interventions: Placebo, Lu AF11167; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: HIV/AIDS, HIV Prevention
Interventions: Tenofovir Douche; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years to 24 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Chapel Hill, North Carolina

Conditions: Solid Tumor
Interventions: ASP1012, Pembrolizumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 5 more

Conditions: Multiple Myeloma
Interventions: Siltuximab, Bortezomib, Placebo, Dexamethasone; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 11
States / cities: Greenbrae, California • Los Angeles, California • Indianapolis, Indiana + 8 more

Conditions: Cancer
Interventions: Afuresertib, Carfilzomib; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
Interventions: Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 36
States / cities: Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more

Conditions: Acute Pain
Interventions: ETR028, ETR029, [ETR028 + ETR029] or HCBT; Drug
Lead sponsor: Elysium Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
Interventions: Nivolumab, Nivolumab + Relatlimab, Ipilimumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hypertension, Fall
Interventions: Tai Chi tailored for lowering blood pressure (PRESSURE), Tai Chi tailored for improving balance (BALANCE); Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Bloomfield, Connecticut

Conditions: Rheumatoid Arthritis
Interventions: RA PRO Dashboard; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Post-traumatic Stress Disorder
Interventions: PARTS Program; Behavioral
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Obesity
Interventions: Implementation Intentions, Fluency Training, Text Messages, Goal Intentions; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults

Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study)

Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

Genetic Variability in CYP2D6 in U.S Active Duty Population

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

The Efficacy of Distal Pharyngeal Airway for Oxygenation During TEE

CYP2C19 Variants and Limonene Metabolism

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors

Metabolomics-Driven Insights Into Ultra-Processed Foods

A Study of PTC923 in Participants With Phenylketonuria

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)

A Study of ASP1012 in Adults With Solid Tumors

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Health Outcomes of Two Different Tai Chi Interventions

Incorporating PRO Data Into RA Clinical Encounters Using Health IT

Program for Alleviating and Resolving Trauma and Stress 1

Implementation Intentions for Weight Loss and Dietary Change in College Students With Overweight and Obesity